0.50 / AMA PRA Category 1 CreditTM 0.50 / CNE Contact Hour
Jointly provided by the Johns Hopkins School of Medicine and the Institute for Johns Hopkins Nursing.
This activity is supported by an educational grant from Kite Pharma.
Chimeric antigen receptor T-cell (CAR-T) therapy has recently emerged as a new treatment strategy for patients with relapsed and refractory leukemia and lymphoma, a patient population that usually has few good treatment options and poor long-term survival. CAR-T therapy is a type of immunotherapy in which autologous T lymphocytes from a patient with cancer are genetically engineered to express a specific synthetic transmembrane protein, known as a chimeric antigen receptor (CAR), on the T-cell surface. This chimeric protein recognizes tumor-related antigens and also stimulates T-cell responses upon antigen recognition. These therapies redirect the patient’s own immune response to target cancer cells resulting in long-lasting antitumor responses. The US Food and Drug Administration recently approved 2 CAR-T therapies, axicabtagene ciloleucel and tisagenlecleucel, for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). In clinical trials of patients with multiple relapsed ALL and DLBCL, these agents have produced much higher response rates than historical treatments, with favorable safety and tolerability profiles. However, treatment resistance remains a significant problem, and a number of options are being examined in order to overcome resistance. The use of CAR-T therapies also requires a high degree of vigilance for common immune-mediated adverse events, such as cytokine release syndrome and neurological toxicities, as well as effective approaches to manage them when they occur. CAR-T therapy represents a significant new advance in the treatment of patients with hematologic malignancies.
This activity is intended for hematology/oncology physicians, nurse practitioners, physician assistants, transplant physicians, and nurses who treat patients with hematologic cancers. No prerequisites required.
After participating in this activity, the participant will demonstrate the ability to:
IDENTIFY the mechanism of action of CAR-Ts and their role in hematologic cancer treatment regimens.
REVIEW the CAR-Ts recently-approved and in-development for hematology/oncology care.
OUTLINE possible CAR-T-related AEs and their implications for hematology/oncology HCPs.
The Johns Hopkins School of Medicine and the Institute for Johns Hopkins Nursing take responsibility for the content, quality, and scientific integrity of this CME/CNE activity.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Johns Hopkins School of Medicine and the Institute for Johns Hopkins Nursing. The Johns Hopkins School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Johns Hopkins School of Medicine designates this enduring material internet activity for a maximum of 0.50 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Contact Hour(s)
The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This 0.50 contact hour educational activity is provided by the Institute for Johns Hopkins Nursing. Claim only those contact hours actually spent in the activity. Statements will be awarded for this educational activity until August 9, 2020.
Policy on Presenter and Provider Disclosure
It is the policy of the Johns Hopkins School of Medicine and the Institute for Johns Hopkins Nursing that the speaker and provider globally disclose conflicts of interest. The Johns Hopkins School of Medicine OCME has established policies in place that will identify and resolve conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to presentation of the education.
Full Disclosure Policy Affecting CME Activities
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins School of Medicine Office of Continuing Medical Education (OCME) requires attested and signed global disclosure of the existence of all financial interests or relationships with commercial interest from any individual in a position to control the content of a CME activity sponsored by OCME.
The following relationships have been reported for this activity:
Dr. Ettinger reports serving as a principal investigator for Golden Biotechnology Corp and serving as a consultant for AbbVie Inc, BeyondSpring Pharmaceuticals, Inc, Boehringer Ingelheim Vetmedica, Inc, Bristol-Myers Squibb Company/sanofi-aventis US LLC, Eli Lilly and Company, Genentech Inc, and Guardant Health Inc.
No other individual with the opportunity to affect this educational content has indicated any financial interests or relationships with a commercial entity.
Note: Grants to investigators at The Johns Hopkins are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
Johns Hopkins School of Medicine Chair and Planner David S. Ettinger, MD Alex Grass Professor of Oncology Sidney Kimmel Comprehensive Cancer Baltimore, Maryland
Faculty Author Patrick Brown, MD Associate Professor of Oncology and Pediatrics Director, Pediatric Leukemia Program Sidney Kimmel Comprehensive Cancer Center Johns Hopkins School of Medicine Baltimore, Maryland
Peer Reviewer Bradley Reames, MD, MS Oncology Fellowship Department of Surgery Johns Hopkins Hospital Baltimore, Maryland
Nurse Planner Rebecca Barshick, RN, MSN Nurse Educator The Institute for Johns Hopkins Nursing Baltimore, Maryland
Nurse Reviewer MiKaela Olsen, APRN-CNS, MS, AOCNS, FAAN Oncology and Hematology Clinical Nurse Specialists Ambulatory Oncology Sidney Kimmel Comprehensive Cancer Center Johns Hopkins School of Medicine Baltimore, Maryland
Off-Label Product Discussion
No faculty member has indicated that his/her presentation will include information on off-label products.
Non-Endorsement of Products
The Institute for Johns Hopkins Nursing and the American Nurses Credentialing Center do not endorse the use of any commercial products discussed or displayed in conjunction with this educational activity.
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of Johns Hopkins School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.
Confidentiality Disclaimer for CME Activity Participant
I certify that I am participating in this Johns Hopkins School of Medicine activity for CME-accredited training and/or educational purposes.
I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the “Privacy Regulations”). Protected health information is information about a person's health or treatment that identifies the person.
I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc.), in any electronic messaging program or through any portable electronic device.
I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.
“The Office of Continuing Medical Education at the Johns Hopkins School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only.”
For CME questions, please contact the CME Office 410-955-2959 or email firstname.lastname@example.org.
Johns Hopkins School of Medicine Office of Continuing Medical Education 720 Rutland Avenue/ Turner 20 Baltimore, Maryland 21205-2195 Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03) (Updated 4/09 and 3/14)
Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.
THE INSTITUTE FOR JOHNS HOPKINS NURSING MISSION STATEMENT
The mission of the Institute for Johns Hopkins Nursing is to share the innovations of Johns Hopkins Nursing in practice, education, and research—locally, nationally, and globally. Our goal in continuing nursing education is to bring you activities that reflect the expertise and creativity of Johns Hopkins Nursing. Our service values are quality, integrity, flexibility, and personal attentiveness. We appreciate your thoughts and welcome your concerns—please feel free to e-mail us: IJHN@.jhmi.edu.
The following is an interactive case module designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an interactive case study, and a CME/CNE post-test and evaluation. All 3 sections must be completed to receive CME/CNE credit. A certificate of participation will be available online immediately following successful completion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact email@example.com regarding ACCME credits or IJHN@.jhmi.edu regarding CNE credits.
Hardware and Software Requirements
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required